EU Sunscreen Ingredients That FDA Has Not Approved: The UV Filter Gap European Brands Must Navigate

Picture a French cosmetics manufacturer with a beautifully engineered SPF 50 sunscreen — fully notified on the CPNP, Cosmetic Product Safety Report signed off by a qualified safety assessor, photostability data in the dossier. The brand has spent years building a loyal European following and is now ready for its first serious push into North America. Then a US regulatory consultant delivers the diagnosis: the sunscreen cannot be legally marketed in the United States. Not because of a labeling error. Not because of a missing claim. Because two of the product’s UV filters simply don’t exist in the American regulatory framework.

This scenario is not hypothetical. We see it repeatedly, and the brands it catches off-guard are rarely small or unsophisticated. Understanding why it happens requires grasping a foundational difference that most European cosmetics teams don’t encounter until it matters most: in the United States, sunscreens are not cosmetics.

The Regulatory Fork in the Road: Cosmetics in the EU, OTC Drugs in the US

EU Regulation (EC) No 1223/2009 classifies sunscreens as cosmetic products. A product intended to protect the skin by filtering solar radiation falls under the same framework as a moisturiser, a shampoo, or a lip balm. The pathway is notification-based: you submit via the Cosmetic Products Notification Portal, confirm that your UV filters appear in Annex VI of the Regulation at or below the permitted maximum concentrations, and demonstrate safety through a two-part Cosmetic Product Safety Report. Regulatory burden is real but the process is predictable and proportionate.

In the United States, the FDA classifies sunscreens as Over-the-Counter (OTC) drugs. The legal basis is Section 201(g) of the Federal Food, Drug, and Cosmetic Act — sunscreen products are “intended to affect the structure or any function of the body” by preventing sunburn and, per FDA’s framing, reducing the risk of skin cancer. That makes them drugs. And OTC drugs must comply with an FDA-issued monograph: a legally binding document specifying exactly which active ingredients are permitted, at what concentrations, under what labeling conditions.

There is no EU-equivalent of “notify and proceed.” You cannot bring a new UV filter to the US market simply because it’s safe and effective by SCCS standards. You must use what FDA has already designated as Generally Recognized as Safe and Effective — GRASE — or go through a separate drug approval pathway. The distinction between those two worlds is where most European sun care brands collide with US regulatory reality.

The UV Filter Count That Should Concern Every European Formulator

EU Annex VI currently lists approximately 27 permitted UV filter substances, each with defined concentration ceilings and conditions of use. The list reflects ongoing SCCS scientific review and includes modern broad-spectrum filters that were specifically developed to improve UVA coverage and reduce the photodegradation problems associated with older chemical filters.

FDA’s 2021 Sunscreen Final Administrative Order — issued under the reformed OTC monograph system introduced by the CARES Act — tells a starkly different story. Of the 16 UV filter ingredients addressed in that order, exactly 2 are classified as GRASE Category I (safe and effective for OTC sunscreen use): zinc oxide and titanium dioxide. Both are inorganic mineral filters. No chemical UV filter achieved GRASE status.

The remaining 14 fall into two categories:

• Category II (not GRASE): PABA and trolamine salicylate. These are off the table entirely — products containing them cannot be marketed as OTC sunscreens.
• Category III (insufficient data): The remaining 12, including avobenzone, oxybenzone, octinoxate, homosalate, octisalate, octocrylene, and six others. These ingredients have been used in US sunscreens for decades, but FDA now says the safety data in the public record does not meet current standards for a GRASE determination.

That alone would be disruptive enough for many European brands. But there’s a second layer of the problem. The UV filters that dominate premium EU formulations — the ones formulators reach for specifically because they offer superior broad-spectrum coverage and better photostability than the legacy chemical filters — are not even addressed in the FDA OTC monograph framework at all.

Bemotrizinol (Tinosorb S), bisoctrizole (Tinosorb M), drometrizole trisiloxane (Mexoryl XL), and diethylamino hydroxybenzoyl hexyl benzoate (Uvinul A Plus) all appear in EU Annex VI. They are widely used in European SPF 30 and SPF 50 products across prestige and mass-market brands. None of them carry GRASE status. A sunscreen containing any of these ingredients cannot be sold as an OTC drug product in the US under the current monograph framework. Full stop.

Twenty Years in the Waiting Room: Why FDA Still Hasn’t Approved Europe’s Best Filters

The obvious question is: why haven’t they been approved? These filters have safety and efficacy records spanning two decades in Europe, Australia, and Canada. The answer is a combination of regulatory bottleneck, genuine scientific caution, and commercial calculation.

Under the old OTC Drug Review process, manufacturers could petition FDA to add a new active ingredient to an OTC monograph through a Time and Extent Application (TEA). Applications for bemotrizinol and bisoctrizole were submitted approximately in 2002–2003. More than 20 years later, neither has received a GRASE determination. The Sunscreen Innovation Act, signed into law in 2014 specifically to accelerate this process, moved the clock very little.

FDA’s stated barrier is the absence of certain safety data by US standards — particularly systemic absorption studies. A 2020 randomised clinical trial published in JAMA (the Journal of the American Medical Association) by FDA researchers found that avobenzone, oxybenzone, octocrylene, and homosalate are all absorbed into the bloodstream at levels exceeding the 0.5 ng/mL threshold that triggers the regulatory requirement for additional non-clinical toxicology studies. This confirmed FDA’s position that even filters with long US market histories need more data — let alone filters like Tinosorb S that have never been used in US-marketed products.

Under the CARES Act’s reformed monograph system, manufacturers can now submit a “Proposed Order” requesting that FDA issue a new Administrative Order adding an ingredient to the sunscreen monograph. The process is theoretically faster than the old TEA route. But it still requires the submitting company to generate and fund the clinical studies FDA demands: maximum usage studies, systemic absorption studies under FDA protocols, and potentially carcinogenicity data if systemic exposure warrants it. Generating a complete FDA-compliant safety package for a novel UV filter costs several million dollars by conservative industry estimates — with no guaranteed approval timeline at the end.

There is one partial exception worth noting. Ecamsule (Mexoryl SX), a filter developed by L’Oréal, received FDA approval via a New Drug Application in 2006. But that NDA covers specific L’Oréal products only. Another brand cannot use ecamsule in their formulation under that approval. The NDA is product-specific, not an open GRASE designation.

Three Routes to the US Market — and What Each One Actually Requires

For a European brand that wants to sell sunscreen in the US, there are three credible paths. None of them is “ship your current EU product unchanged.”

Reformulate for the US market. This means building a US-specific version of the product using only GRASE Category I filters (zinc oxide, titanium dioxide, or both), or — accepting some regulatory uncertainty — using Category III filters, which are still currently permitted in OTC sunscreens while FDA’s review is ongoing. Most premium European brands resist a switch to purely mineral formulations because of aesthetics: mineral filters, particularly at higher concentrations, can leave a white cast and have different sensory profiles. But reformulation is the cleanest compliance path and eliminates the core risk.

Pursue a New Drug Application for the specific product. If a brand has a flagship product they are deeply committed to bringing to market in its EU formulation, an NDA is the only route. It’s expensive — typically requiring three to five years of regulatory and clinical work — and requires US-based regulatory operations or experienced external counsel. It is also the only pathway that, if successful, creates a proprietary approved product that competitors cannot replicate without their own NDA. For brands with sufficiently large US revenue projections, the economics can work. For SMEs making their first US entry, they rarely do.

Restructure the product as a cosmetic by removing UV protection claims. Some sunscreen-adjacent formulations — a tinted moisturiser with incidental UV-filtering ingredients, for instance — could potentially avoid OTC drug classification if no therapeutic UV protection claims are made on primary labeling. This is genuinely narrow territory. FDA and the FTC both scrutinise implied drug claims, and any suggestion that a product prevents sunburn or reduces skin cancer risk on the label, in advertising, or even on a brand’s website can trigger OTC drug status regardless of how the product is otherwise positioned. This route requires close legal and regulatory review and should not be attempted without experienced US regulatory counsel confirming the approach.

There is a fourth compliance consideration that sits alongside all three routes: labeling conventions differ significantly and must be adapted regardless of which path you choose. FDA limits “water resistant” claims to exactly two time periods — 40 minutes or 80 minutes — stated in parentheses on the principal display panel. EU labeling conventions use “water resistant” or “very water resistant” without time designations. And for SPF values above 50, FDA requires the label to state “SPF 50+” rather than the specific tested number, since the Agency considers numerical precision above 50 to be misleading to consumers. A product tested and labeled as SPF 75 in France must be relabeled “SPF 50+” for US distribution.

What to Do Before You Spend on US Distribution

The UV filter gap is not unsolvable. But it does need to be discovered and addressed at the formulation stage, not after you’ve signed with a US distributor or invested in a retailer presentation.

Before you allocate meaningful US market entry budget, commission a UV filter compatibility analysis against the current FDA OTC monograph framework for every sun care SKU you intend to sell stateside. Know which of your active ingredients are GRASE Category I, which are Category III (permitted but under scrutiny), and which are simply outside the US OTC system altogether. That analysis is straightforward for any team with US regulatory expertise and costs a fraction of what reformulation, returned inventory, or a US market launch delay will cost you later.

Our team works with European cosmetics manufacturers at precisely this intersection — EU compliance documentation and North American market entry requirements. The sunscreen UV filter gap is one of the most consistently underestimated obstacles we encounter. Plan for it at the outset, and the path forward is clear.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Care Europe | VP Operations, Qalitex. Learn more about our team

Talk to our team about EU market entry and US compliance strategy. Contact us

Related from our network

• US FDA 21 CFR Compliance for Cosmetics and OTC Products — Qalitex Laboratories provides ISO 17025-accredited testing and US compliance documentation support for brands navigating FDA OTC drug and cosmetic requirements.
• Testing and Compliance Support for North American Market Entry — Androxa offers Health Canada and FDA pre-market compliance support, including ingredient safety dossiers and GMP verification for brands entering the Canadian and US markets.